Glucocorticoids are highly effective in treating polymyalgia rheumatica and giant cell arteritis, but their use is associated with numerous adverse events. Therefore, it is important to use them for the shortest period of time possible. The published evidence suggests that discontinuation of GCis feasible in a substantial number of patients with polymyalgia rheumaticaand giant cell arteritis after an adequate period of treatment, provided that glucocorticoids are tapered gradually. Recurrences are relatively infrequent in polymyalgia rheumatica and somewhat more common in giant cell arteritis. Immunosuppressive agents may be used in patients with frequently relapsing or recurring disease to decrease exposure to glucocorticoids.
|Journal||Clinical and Experimental Rheumatology|
|Publication status||Published - 2013|
- Discontinuation of therapy
- Giant cell arteritis
- Polymyalgia rheumatica
ASJC Scopus subject areas
- Immunology and Allergy